Barcode technology in healthcare

Datawords Group, a Multicultural Ingenuity™[1] expert, acquires Switching-Time with the support of Keensight Capital to empower international brands with digital campaign solutions in China

Retrieved on: 
Friday, December 2, 2022

Datawords relies on both MULTIdigital expertiseand CULTURAL adaptation of brand content across more than 50 languages and countries to capture local relevancy.

Key Points: 
  • Datawords relies on both MULTIdigital expertiseand CULTURAL adaptation of brand content across more than 50 languages and countries to capture local relevancy.
  • To reinforce its position in the Chinese market, Datawords today announces the acquisition of the award-winning integrated communication company Switching-Time, founded in Shanghai, China.
  • Established in 2012, Switching-Time serves a prestigious set of clients in the fashion, beauty, luxury and lifestyle industries.
  • Over the years, it has expanded its offering to cover the full breadth of digital marketing services, including public relations (e-PR), influencer digital marketing and social media.

Ibex Medical Analytics Secures $10M Funding from Kreos Capital

Retrieved on: 
Wednesday, November 9, 2022

TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ --  Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced it had secured $10 million in funding from Kreos Capital.

Key Points: 
  • Kreos Capital, a leading growth debt provider, invests $10 million to accelerate Ibex's AI deployments and new customers, paving way for further expansions
    TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced it had secured $10 million in funding from Kreos Capital .
  • The funding comes as an addition to Ibex's $52 million funding to date , with investors including Octopus Ventures, 83North, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital.
  • Aris Constantinides, General Partner of Kreos Capital commented, "We are proud to be able to support the Ibex team in their endeavors to transform cancer diagnosis with AI.
  • Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient.

Valiantys To Acquire Addteq, Inc.'s Consulting Business to Deepen Atlassian Services and Capabilities in North America

Retrieved on: 
Thursday, November 3, 2022

PARIS and BOSTON, Nov. 3, 2022 /PRNewswire/ -- Valiantys, a leading global Atlassian consulting and services firm, today announced it has signed a definitive agreement to acquire the Atlassian services division of Addteq, Inc. ("Addteq"). This acquisition will be made possible by the investment and operational support of Keensight Capital, one of the leading private equity managers dedicated to international Growth Buyout1 investments, and Valiantys' majority shareholder since June 2022.

Key Points: 
  • PARIS and BOSTON, Nov. 3, 2022 /PRNewswire/ -- Valiantys , a leading global Atlassian consulting and services firm, today announced it has signed a definitive agreement to acquire the Atlassian services division of Addteq, Inc. ("Addteq").
  • "This strategic acquisition will deepen Valiantys' services capabilities, strengthen its coverage of the financialservices andhealthcaresectors, andreinforceitscoverageoftheUSEast coastregion,"saidLucasDussurget, Global CEO at Valiantys.
  • As an Atlassian Platinum Partner, Addteq has an impressive track record in deployments and Managed Services of Atlassian solutions.
  • We are thrilled to welcome them to the Valiantys team," said Emmanuel Benoit, North America CEO at Valiantys.

Valiantys To Acquire Addteq, Inc.'s Consulting Business to Deepen Atlassian Services and Capabilities in North America

Retrieved on: 
Thursday, November 3, 2022

PARIS and BOSTON, Nov. 3, 2022 /PRNewswire/ -- Valiantys, a leading global Atlassian consulting and services firm, today announced it has signed a definitive agreement to acquire the Atlassian services division of Addteq, Inc. ("Addteq"). This acquisition will be made possible by the investment and operational support of Keensight Capital, one of the leading private equity managers dedicated to international Growth Buyout1 investments, and Valiantys' majority shareholder since June 2022.

Key Points: 
  • PARIS and BOSTON, Nov. 3, 2022 /PRNewswire/ -- Valiantys , a leading global Atlassian consulting and services firm, today announced it has signed a definitive agreement to acquire the Atlassian services division of Addteq, Inc. ("Addteq").
  • "This strategic acquisition will deepen Valiantys' services capabilities, strengthen its coverage of the financialservices andhealthcaresectors, andreinforceitscoverageoftheUSEast coastregion,"saidLucasDussurget, Global CEO at Valiantys.
  • As an Atlassian Platinum Partner, Addteq has an impressive track record in deployments and Managed Services of Atlassian solutions.
  • We are thrilled to welcome them to the Valiantys team," said Emmanuel Benoit, North America CEO at Valiantys.

Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round

Retrieved on: 
Tuesday, October 18, 2022

These additional funds follow the Companys recent $41.5M Series C-2 equity financing announced in February 2022.

Key Points: 
  • These additional funds follow the Companys recent $41.5M Series C-2 equity financing announced in February 2022.
  • We are very pleased to partner with Kreos Capital as we seek to revolutionize the precision medicine markets said Haim Neerman, CEO of Variantyx.
  • Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets.
  • Kreos Capital is the leading growth debt provider in Europe and Israel, backing high-growth companies through every stage of their life-cycle.

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital

Retrieved on: 
Thursday, September 15, 2022

TEL AVIV, Israel, Sept. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the Company has entered into a $40 million non-dilutive secured debt financing agreement with Kreos Capital, a leading provider of innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.

Key Points: 
  • Per the terms of the agreement, the first tranche of $10 million was made available to BioLineRx upon execution of the definitive agreement, subject to customary conditions to closing.
  • Borrowings under the financing will bear interest at a fixed rate of 9.5% per annum (~11.0%, including associated cash fees).
  • In addition, Kreos will be entitled to mid-to-high single-digit royalties on Motixafortide sales, up to a pre-defined cap.
  • Kreos Capital is a leading growth debt provider in Europe and Israel, backing high-growth companies through every stage of their life cycle.

Leading Atlassian Partner Valiantys Secures Investment from Tercera to Expand Its Global Reach

Retrieved on: 
Thursday, July 21, 2022

TOULOUSE, France and BOSTON, July 21, 2022 /PRNewswire/ -- Valiantys, a global Atlassian consulting and services firm, today announced that Tercera, a growth equity firm specializing in cloud professional services, has made a minority investment with a specific focus on expanding in the Americas and other key regions. This infusion of capital comes alongside a majority investment by Keensight Capital, one of the leading private equity managers dedicated to pan-European growth buyout investments.

Key Points: 
  • With these new funds, Valiantys will expand its service offerings for Atlassian products and extend its reach across the globe via both organic growth and strategic M&A in key markets.
  • "Our focus has always been to help companies accelerate their agile transformation journey and to be Atlassian's partner of choice," said Lucas Dussurget, CEO at Valiantys.
  • Valiantys has been recognized as an Atlassian Partner of the Year in six of the past seven years and helped to found the Atlassian Partner Council where it is still an active member.
  • Valiantys is a leading global consulting and services firm dedicated to Atlassian.

TIS Secures €50 Million Debt Facility From Kreos Capital

Retrieved on: 
Tuesday, June 7, 2022

HEIDELBERG, Germany, June 07, 2022 (GLOBE NEWSWIRE) -- Today, enterprise B2B payments leader Treasury Intelligence Solutions (TIS) announced the successful arrangement of a new debt facility with Kreos Capital that will provide up to 50 million in financing.Kreos Capital,the leading growth debt provider in Europe, facilitated the deal to provide TIS with additional funding to execute a variety of strategic initiatives involving new product innovations, potential acquisitions, and continued geographic expansion.

Key Points: 
  • HEIDELBERG, Germany, June 07, 2022 (GLOBE NEWSWIRE) -- Today, enterprise B2B payments leader Treasury Intelligence Solutions (TIS) announced the successful arrangement of a new debt facility with Kreos Capital that will provide up to 50 million in financing.Kreos Capital,the leading growth debt provider in Europe, facilitated the deal to provide TIS with additional funding to execute a variety of strategic initiatives involving new product innovations, potential acquisitions, and continued geographic expansion.
  • According to Erik Masing , CEO of TIS, "Working with Kreos creates the ideal conditions for pursuing the company's aggressive business objectives.
  • For Kreos Capital, TIS represents both an early investment from Kreos' seventh investment fund, and an ideal business partner to support with financing due to their consistent track record of growth.
  • With over 2.0 billion in current funds under management, Kreos can invest between 2 million and 100 million per transaction in both public and private companies across stages.

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

Retrieved on: 
Wednesday, April 6, 2022

The loan facility is comprised of three tranches in the amount of $10.0 million, $2.5 million, and $2.5 million, respectively, with a drawdown of the first tranche available upon the execution of the agreement.

Key Points: 
  • The loan facility is comprised of three tranches in the amount of $10.0 million, $2.5 million, and $2.5 million, respectively, with a drawdown of the first tranche available upon the execution of the agreement.
  • The senior secured loan initially bears interest at a rate of 9.25%, which may be reduced to 8.75% upon reaching certain milestones.
  • The loan is prepayable in full, at any time at the option of PolyPid.
  • The loan is secured by PolyPid's owned equipment and intellectual property, and the Company will pay a customary fee to Kreos for the establishment of the loan.

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

Retrieved on: 
Wednesday, March 30, 2022

The two agreements, together with VectivBios cash and cash equivalents as of December 31, 2021 of $103 million, provides up to $220 million in operating capital.

Key Points: 
  • The two agreements, together with VectivBios cash and cash equivalents as of December 31, 2021 of $103 million, provides up to $220 million in operating capital.
  • VectivBio is also eligible to receive tiered, double-digit, escalating royalties on sales of apraglutide in Japan.
  • Asahi Kasei Pharma has a right to participate in the development of new indications and lead and fund all development, registration and commercialization activities in Japan.
  • This agreement accelerates the development of apraglutide in Japan, a key market outside our core commercial strategy.